Literature DB >> 16133690

Association of estrogen receptor alpha gene microsatellite polymorphism with annual changes in bone mineral density in Korean women with hormone replacement therapy.

Chang Hoon Yim1, Jong Tae Choi, Hyun Ah Choi, Young Soon Kang, In Gul Moon, Hyun Koo Yoon, In Kwon Han, Dae Hee Kang, Ki Ok Han.   

Abstract

Variation in drug response to hormone replacement therapy (HRT) may reflect genetic heterogeneity in the estrogen-related genes, possibly including estrogen receptor alpha (ERalpha) gene. However, only a few association studies of the drug response to HRT have been reported, focusing mainly on the intronic polymorphisms of the ERalpha gene. We therefore examined 284 postmenopausal women (mean age, 52.2 +/- 5.0 years) for the microsatellite thymine-adenine (TA) repeat polymorphism in the promoter of the ERalpha gene and its relationship to drug response by measuring changes in bone mineral density (BMD) after 1 year of HRT. In our study population, the most common number of TA repeats was 14, with a range of values between 11 and 27. At baseline, the number of TA repeats was neither associated with measured lumbar spine or femoral neck BMD nor with bone markers. When we categorized the subjects by the TA repeat numbers into an L group (n = 142), with a low mean number of repeats (TA < 16), and an H group (n = 142), with a high mean number of repeats (TA > or = 16), no significant genotypic differences were noted in spinal or femoral neck BMD or in bone markers. However, the drug response on lumbar spine BMD after 1 year of HRT correlated with the mean number of TA repeats (r = -0.131, P = 0.035) after adjustment for confounding factors such as body mass index and years since menopause. This correlation was also seen with the number of TA repeats on the shorter allele (r = -0.159, P = 0.012), which was defined as the allele with the lower number of TA repeats. However, this genotypic association was not found in the femoral neck BMD (r = 0.053, P = 0.396). When we defined the nonresponder group as women who had lost BMD even with HRT, 15.9% of the subjects were included, and this group was significantly younger and had higher initial BMD than the responder group. After further adjustment for age and initial BMD, the number of TA repeats on the shorter allele remained significantly associated with drug responsiveness (P = 0.005). These data indicate significant effects of the ERalpha TA repeat polymorphism on the estrogen responsiveness of lumbar spine BMD after 1 year of HRT in Korean women.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133690     DOI: 10.1007/s00774-005-0619-2

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  21 in total

Review 1.  Therapeutic approaches to bone diseases.

Authors:  G A Rodan; T J Martin
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

2.  Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.

Authors:  M Komulainen; H Kröger; M T Tuppurainen; A M Heikkinen; R Honkanen; S Saarikoski
Journal:  Osteoporos Int       Date:  2000       Impact factor: 4.507

3.  Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen.

Authors:  Noriko Kobayashi; Takafumi Fujino; Toru Shirogane; Itsuko Furuta; Yoko Kobamatsu; Minoru Yaegashi; Noriaki Sakuragi; Seiichiro Fujimoto
Journal:  Maturitas       Date:  2002-03-25       Impact factor: 4.342

4.  Nonassociation of estrogen receptor genotypes with bone mineral density and estrogen responsiveness to hormone replacement therapy in Korean postmenopausal women.

Authors:  K O Han; I G Moon; Y S Kang; H Y Chung; H K Min; I K Han
Journal:  J Clin Endocrinol Metab       Date:  1997-04       Impact factor: 5.958

5.  Heritable and life-style determinants of bone mineral density.

Authors:  E A Krall; B Dawson-Hughes
Journal:  J Bone Miner Res       Date:  1993-01       Impact factor: 6.741

Review 6.  Insights from the study of animals lacking functional estrogen receptor.

Authors:  K S Korach
Journal:  Science       Date:  1994-12-02       Impact factor: 47.728

7.  Fragile X premutations and (TA)n estrogen receptor polymorphism in women with ovarian dysfunction.

Authors:  M Syrrou; I Georgiou; P C Patsalis; I Bouba; G Adonakis; G N Pagoulatos
Journal:  Am J Med Genet       Date:  1999-05-28

8.  Estrogen receptor alpha gene polymorphisms and bone mineral density: haplotype analysis in women from the United Kingdom.

Authors:  O M Albagha; F E McGuigan; D M Reid; S H Ralston
Journal:  J Bone Miner Res       Date:  2001-01       Impact factor: 6.741

9.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.

Authors:  Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

10.  Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.

Authors:  E P Smith; J Boyd; G R Frank; H Takahashi; R M Cohen; B Specker; T C Williams; D B Lubahn; K S Korach
Journal:  N Engl J Med       Date:  1994-10-20       Impact factor: 91.245

View more
  6 in total

1.  The genetics of response to estrogen treatment.

Authors:  Bente L Langdahl
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 2.  Postmenopausal hormone therapy: an Endocrine Society scientific statement.

Authors:  Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian
Journal:  J Clin Endocrinol Metab       Date:  2010-06-21       Impact factor: 5.958

3.  Bone mass pharmacogenetics and ethnic health implications.

Authors:  Francesco Massart; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2007-05

4.  The role of estrogen receptor-alpha gene TA polymorphism and aromatase gene TTTA polymorphism on peak bone mass attainment in males: is there an additive negative effect of certain allele combinations?

Authors:  Darko Kastelan; Zorana Grubic; Ivana Kraljevic; Ozren Polasek; Tina Dusek; Katarina Stingl; Vesna Kerhin-Brkljacic; Mirko Korsic
Journal:  J Bone Miner Metab       Date:  2009-01-27       Impact factor: 2.626

Review 5.  Polymorphisms of estrogen receptors and risk of depression: therapeutic implications.

Authors:  Joanne Ryan; Marie-Laure Ancelin
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

6.  Simvastatin induces estrogen receptor-alpha (ER-alpha) in murine bone marrow stromal cells.

Authors:  Chunli Song; Jingying Wang; Quansheng Song; Xu Li; Zhongqiang Chen; Qingjun Ma; Zhongjun Liu; Hongti Jia; Gengting Dang
Journal:  J Bone Miner Metab       Date:  2008-05-11       Impact factor: 2.626

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.